Future Trial – Small Fiber Neuropathy
Open for enrollment
What is the Purpose of this Study?
To determine the efficacy, safety and tolerability of Fycompa compared to placebo in treating Neuropathy.
Who is Eligible to Participate?
Patients 18 to 60 years old with a confirmed diagnosis of small fiber neuropathy proven by a skin biopsy. Patients will also have to meet all inclusion criteria which will be explained in greater detail b the study coordinator.
What is involved in this Study?
Patients will take oral Fycompa, titrating dose for several weeks and then switch over to Placebo or take oral Placebo, titrating dose for several weeks and then switch over to Fycompa.
How long is the Study?
This study will be approximately 6 months long.
For more information contact:
Lynette McKinney, MSCS, CRC, Study Coordinator at 602-358-2271 or email@example.com